Screener
Aquestive Therapeutics, Inc. AQST Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:08 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000030
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable | (17,973) | 1,905 |
| Accrued expenses and other liabilities | (2,803) | (2,776) |
| Deferred revenue | (272) | (261) |
| Net cash used for operating activities | (14,806) | (23,400) |
| Investing activities: | ||
| Capital expenditures | (52) | (135) |
| Net cash used for investing activities | (52) | (135) |
| Financing activities: |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s operating cash flow?
- Aquestive Therapeutics, Inc. (AQST) reported operating cash flow of -$14.81M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Aquestive Therapeutics, Inc.'s operating cash flow increased by 36.7% year-over-year, from -$23.4M to -$14.81M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s operating cash flow?
- Over 3 years (2021 to 2025), Aquestive Therapeutics, Inc.'s operating cash flow has grown at a 16.7% compound annual growth rate (CAGR), from -$32.98M to -$52.43M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Aquestive Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude